Preliminary data from a phase 1b extension study (NCT05292911) involving 64 individuals with MRI-PDFF 10% and BMI 28 kg/m 2 demonstrated that 50%, 44%, and 60% of participants presenting baseline alanine aminotransferase (ALT) 30 IU/L reached combined MRI-PDFF reduction 30% and ALT reduction 17 IU/L at pemvidutide doses of 1.2, 1.8, and 2.4 mg, respectively, vs
The pulsatile release more closely mimics your bodys natural GH pattern post-exercise, potentially optimising anabolic signalling
Shorter wait times and direct prescriber-to-pharmacy coordination can streamline treatment initiation
Late-Breaking Clinical Trials VII (Session 112) Monday, March 30, 10:4511:45 AM CT, Main Tent, Great Hall Primary Efficacy and Safety Results From the Phase 3 Sirolimus-Coated Balloon For Infra-inguinal Peripheral Arterial Disease (SirPAD) Trial
MICC works best when paired with healthy eating, regular exercise, and follow-up visits with your healthcare provider.